Jove
Visualize
Contact Us

Related Experiment Videos

Ablative therapies for Barrett's esophagus.

M B Fennerty

    The American Journal of Managed Care
    |February 24, 2001
    PubMed
    Summary

    Barrett's esophagus (BE) treatments focus on normalizing acid. While reversal and ablative therapies aren't for all BE patients, specific subgroups may benefit from these advanced techniques.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia.

    Alimentary pharmacology & therapeutics·2011
    Same author

    Randomised clinical trial: MiraLAX vs. Golytely - a controlled study of efficacy and patient tolerability in bowel preparation for colonoscopy.

    Alimentary pharmacology & therapeutics·2010
    Same author

    Clinical trial: lansoprazole 15 or 30 mg once daily vs. placebo for treatment of frequent nighttime heartburn in self-treating subjects.

    Alimentary pharmacology & therapeutics·2009
    Same author

    Decreasing prevalence combined with increasing eradication of Helicobacter pylori infection in the United States has not resulted in fewer hospital admissions for peptic ulcer disease-related complications.

    Alimentary pharmacology & therapeutics·2007
    Same author

    Review article: alternative approaches to the long-term management of GERD.

    Alimentary pharmacology & therapeutics·2005
    Same author

    Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis.

    Alimentary pharmacology & therapeutics·2005
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies

    Area of Science:

    • Gastroenterology
    • Esophageal Diseases
    • Oncology

    Background:

    • Barrett's esophagus (BE) involves esophageal metaplasia.
    • Current BE treatments primarily aim to normalize the esophageal acid environment.
    • The transition from squamous to columnar epithelium in BE is linked to acid exposure.

    Purpose of the Study:

    • To review emerging therapies for Barrett's esophagus beyond acid normalization.
    • To evaluate the potential benefits of reversal and ablative techniques in BE.
    • To identify specific patient subgroups who may benefit from advanced BE therapies.

    Main Methods:

    • Literature review of current and investigational BE treatments.
    • Analysis of data supporting reversal and ablative techniques.
    • Identification of patient criteria for advanced therapies.

    Main Results:

    • Acid normalization remains a primary treatment strategy for BE.
    • Reversal and ablative therapies show promise but lack generalizable data for all BE patients.
    • Certain BE subgroups may be suitable candidates for these advanced treatments.

    Conclusions:

    • While acid suppression is standard, novel therapies are being explored for BE.
    • Further research is needed to define the role of reversal and ablative techniques.
    • Personalized treatment approaches may benefit specific Barrett's esophagus patient subgroups.

    Related Experiment Videos